Theravance Biopharma, Inc. logo TBPH - Theravance Biopharma, Inc.

Price: -- -- | CONSENSUS: Hold DETAILS
STRONG
BUY
0
BUY 6
HOLD 7
SELL 3
STRONG
SELL
0
| PRICE TARGET: $27.00 DETAILS
HIGH: $40.00
LOW: $14.00
MEDIAN: $27.00
CONSENSUS: $27.00
UPSIDE: 64.94%
Metric 2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011
Revenue
Revenue 107.5 64.4 57.4 51.3 55.3 71.9 73.4 60.4 15.4 48.6 42.1 11.7 0.2 130.1 14.9
Cost of Revenue 5.5 0 40.6 63.4 193.7 0 0 0.7 6.0 2.9 4.7 4.1 120.6 114.0 3.8
Gross Profit 101.9 64.4 16.8 (12.0) (138.3) 71.9 73.4 59.7 9.4 45.8 37.5 7.6 (120.4) 16.1 11.0
Operating Expenses
R&D Expenses 37.4 37.6 46.3 70.1 201.5 261.0 219.2 201.3 173.9 141.7 129.2 168.5 120.6 114.0 98.8
SG&A Expenses 73.7 69.2 70.5 67.1 99.3 108.5 106.1 97.1 95.6 84.5 90.2 71.6 35.9 25.7 21.5
Other Expenses 4.1 4.5 (44.0) (57.2) (181.4) 0 0 0 0 0 0 0 0 0 0
Operating Expenses 115.2 111.3 72.8 79.9 119.4 369.5 325.3 298.4 269.5 226.2 219.4 240.2 156.5 139.7 120.3
Operating Income
Operating Income (13.2) (46.9) (56.0) (92.0) (257.8) (297.6) (251.9) (238.8) (260.1) (180.5) (181.9) (232.5) (156.3) (9.6) (109.3)
Interest Expense 2.5 2.5 2.4 6.4 8.5 8.5 31.9 10.5 8.5 1.4 0 0 0 0 0
Interest Income 0 4.9 9.1 8.5 1.1 4.4 8.4 12.0 4.8 1.3 0.6 1.9 0 0 0
Profitability
EBITDA (7.7) (38.5) (51.6) (76.1) (232.8) (287.8) (203.6) (212.4) (259.1) (176.0) (178.8) (228.0) (153.6) (6.3) (105.5)
EBIT (13.2) (42.1) (53.6) (79.1) (237.6) (294.8) (209.8) (215.6) (263.2) (179.2) (181.3) (230.7) (156.3) (9.6) (109.3)
Income Before Tax 129.2 (44.6) (49.3) (92.8) (265.2) (303.3) (241.7) (226.1) (271.7) (180.6) (181.3) (230.7) (156.3) (9.6) (109.3)
Income Tax Expense 23.4 11.8 5.9 0.0 (0.2) (8.5) (5.2) (10.6) 13.7 10.1 1.0 6.4 0 0 0
Net Income 105.9 (56.4) (55.2) 872.1 (199.4) (278.0) (236.5) (215.5) (285.4) (190.7) (182.2) (237.0) (156.3) (9.6) (109.3)
Per Share Data
EPS (Basic) 2.10 -1.15 -1.00 -1.26 -2.87 -4.46 -4.25 -3.99 -5.45 -4.26 -5.34 -7.46 -4.92 -0.30 -3.43
EPS (Diluted) 2.06 -1.15 -1.00 -1.26 -2.87 -4.46 -4.25 -3.99 -5.45 -4.26 -5.34 -7.46 -4.84 -0.30 -3.43
Shares Outstanding 50.3 48.8 55.3 73.6 69.5 62.3 55.6 54.0 52.4 44.7 34.1 31.8 31.7 31.7 31.9
Metric 2025 2024 2023 2022 2021 2020 2019 2018 2017 2016
Current Assets
Cash & Cash Equivalents 167.8 37.8 39.5 298.2 90.0 81.5 58.1 378.0 89.0 344.7
Short-Term Investments 147.6 50.6 62.9 29.3 83.5 211.5 222.8 127.3 259.6 156.4
Net Receivables 95.5 68.4 17.5 16.8 57.6 69.7 50.6 10.7 9.4 9.7
Inventory 0 0 0 0 0 0 0 0 16.8 12.2
Other Current Assets 7.6 4.2 11.6 7.7 8.6 10.4 7.1 0 3.7 2.4
Total Current Assets 418.5 161.1 133.5 353.5 249.9 393.3 338.5 532.8 378.7 528.5
Non-Current Assets
Property, Plant & Equipment 30.3 35.8 45.4 52.0 53.3 59.7 59.2 13.2 10.2 8.5
Goodwill 0 0 0 0 0 0 0 0 0 0
Intangible Assets 0 0 0 0 0 0 0 0 0 0
Long-Term Investments 14.3 0 0 0 68.4 0.8 9.5 11.9 41.6 91.6
Other Non-Current Assets 22.5 157.3 203.1 201.9 3.2 15.2 1.6 2.4 10.9 10.7
Total Non-Current Assets 67.1 193.1 248.5 253.9 124.9 75.7 70.3 27.4 62.7 110.8
Total Assets 485.6 354.2 382.0 607.4 374.8 469.1 408.8 560.2 441.4 639.3
Current Liabilities
Account Payables 2.6 2.2 1.5 1.6 3.1 6.8 4.8 9.0 5.9 1.7
Short-Term Debt 10.9 0 0 0 17.4 29.2 17.6 0 0 0
Deferred Revenue 0 0 0 0.0 0.1 11.5 31.6 43.4 0.1 0.2
Other Current Liabilities 19.5 0 12.9 (0.0) 25.2 40.8 29.6 22.3 32.4 33.4
Total Current Liabilities 38.3 32.1 24.8 28.7 58.6 123.6 111.7 98.6 62.6 49.3
Non-Current Liabilities
Long-Term Debt 32.8 0 0 0 599.4 599.8 445.2 454.4 223.7 222.7
Deferred Tax Liabilities 85.7 0 0 0 0.2 0 0 (26.2) 0 0
Other Non-Current Liabilities 0.3 107.4 99.0 91.3 2.2 1.8 21.3 32.7 39.9 17.1
Total Non-Current Liabilities 150.5 146.5 144.2 136.9 654.8 649.2 521.0 513.3 263.7 239.8
Total Liabilities 188.8 178.6 169.0 165.6 713.4 772.8 632.7 611.8 326.2 289.0
Stockholders' Equity
Common Stock 0.0 0 0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
Retained Earnings (859.6) (965.5) (909.1) (853.9) (1,726.0) (1,526.6) (1,248.6) (1,012.1) (797.7) (512.2)
Accumulated Other Comprehensive Income 0.1 0.0 (0.1) (0.0) 0 0.0 0.1 (0.2) (0.7) (0.3)
Total Stockholders' Equity 296.7 175.5 213.0 441.8 (338.6) (303.8) (223.8) (51.6) 115.2 350.2
Total Liabilities & Equity 485.6 354.2 382.0 607.4 374.8 469.1 408.8 560.2 441.4 639.3
Debt Metrics
Total Debt 75.5 49.8 49.2 52.2 669.5 676.3 510.5 454.4 223.7 222.7
Net Debt (92.3) 12.0 9.6 (246.0) 579.6 594.8 452.5 76.3 134.8 (122.0)
Metric 2025 2024 2023 2022 2021 2020 2019 2018 2017 2016
Operating Activities
Net Income 105.9 (56.4) (55.2) (92.8) (265.1) (294.8) (236.5) (215.5) (285.4) (190.7)
Depreciation & Amortization 5.6 3.6 4.3 7.0 8.6 7.0 6.2 3.2 4.0 3.1
Stock-Based Compensation 18.5 21.4 25.4 39.7 62.1 63.0 60.5 51.3 49.1 41.2
Change in Working Capital 120.5 20.4 (8.3) 42.4 (39.5) (37.8) (45.4) 59.4 22.4 46.9
Other Non-Cash Items (0.4) 7.1 3.7 (183.3) 26.1 12.2 (23.0) (0.0) 0.0 0.2
Operating Cash Flow 238.5 (11.5) (27.0) (187.0) (207.9) (250.4) (238.2) (112.9) (201.1) (99.0)
Investing Activities
Capital Expenditure (0.0) (0.3) (2.5) (0.6) (3.4) (6.6) (3.2) (7.2) (2.4) (2.1)
Acquisitions 0 0 0 0 0 0 5 20 0 0
Purchases of Investments (248.2) (143.0) (134.5) (103.1) (158.3) (402.0) (423.9) (183.3) (288.8) (237.6)
Sales/Maturities of Investments 143.0 155.7 102.8 158.0 286.2 419.3 339.0 347.2 234.9 91.5
Other Investing Activities 0 0 1.5 1,099.7 0.0 0.1 0.0 0.0 (53.9) (146.1)
Investing Cash Flow (105.3) 12.3 (32.7) 1,154.0 124.5 10.7 (83.1) 176.7 (56.3) (148.2)
Financing Activities
Net Debt Issuance 0 0 0 (631.6) (10.7) 144.7 (2.2) 229.4 0 222.5
Stock Repurchased (4.0) (3.1) (199.6) (132.3) (9.1) (9.7) (3.2) (9.8) (8.6) (3.9)
Dividends Paid 0 0 0 0 0 0 0 0 0 0
Other Financing Activities 0 0.5 0.6 5.1 3.5 (11.7) 6.6 5.6 10.2 7.6
Financing Cash Flow (3.2) (2.5) (198.9) (758.8) 91.9 263.1 1.3 225.2 1.7 479.2
Cash Position
Net Change in Cash 130.0 (1.7) (258.6) 208.2 8.5 23.4 (320.0) 289.0 (255.7) 232.0
Cash at Beginning 38.6 40.4 299.0 90.8 82.3 58.9 378.9 89.8 344.7 112.7
Cash at End 168.6 38.6 40.4 299.0 90.8 82.3 58.9 378.9 89.0 344.7
Free Cash Flow 238.5 (11.9) (29.5) (187.6) (211.3) (257.0) (241.4) (120.1) (203.5) (101.1)
Key Metrics 2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011
Income Statement
Revenue 107.5 64.4 57.4 51.3 55.3 71.9 73.4 60.4 15.4 48.6 42.1 11.7 0.2 130.1 14.9
Gross Profit 101.9 64.4 16.8 (12.0) (138.3) 71.9 73.4 59.7 9.4 45.8 37.5 7.6 (120.4) 16.1 11.0
Operating Income (13.2) (46.9) (56.0) (92.0) (257.8) (297.6) (251.9) (238.8) (260.1) (180.5) (181.9) (232.5) (156.3) (9.6) (109.3)
Net Income 105.9 (56.4) (55.2) 872.1 (199.4) (278.0) (236.5) (215.5) (285.4) (190.7) (182.2) (237.0) (156.3) (9.6) (109.3)
EPS (Diluted) 2.06 -1.15 -1.00 -1.26 -2.87 -4.46 -4.25 -3.99 -5.45 -4.26 -5.34 -7.46 -4.84 -0.30 -3.43
Balance Sheet
Cash & Equivalents 167.8 37.8 39.5 298.2 90.0 81.5 58.1 378.0 89.0 344.7
Total Assets 485.6 354.2 382.0 607.4 374.8 469.1 408.8 560.2 441.4 639.3
Total Debt 75.5 49.8 49.2 52.2 669.5 676.3 510.5 454.4 223.7 222.7
Stockholders' Equity 296.7 175.5 213.0 441.8 (338.6) (303.8) (223.8) (51.6) 115.2 350.2
Cash Flow
Operating Cash Flow 238.5 (11.5) (27.0) (187.0) (207.9) (250.4) (238.2) (112.9) (201.1) (99.0)
Capital Expenditure (0.0) (0.3) (2.5) (0.6) (3.4) (6.6) (3.2) (7.2) (2.4) (2.1)
Free Cash Flow 238.5 (11.9) (29.5) (187.6) (211.3) (257.0) (241.4) (120.1) (203.5) (101.1)